Vissers,P.A.J.Mols,F.Thong,M.S.Y.Pouwer,F.Vreugdenhil,G.van de Poll-Franse,L.V.2025-02-012025-02-012015Vissers, P A J, Mols, F, Thong, M S Y, Pouwer, F, Vreugdenhil, G & van de Poll-Franse, L V 2015, 'The impact of diabetes on neuropathic symptoms and receipt of chemotherapy among colorectal cancer patients : Results from the PROFILES registry', Journal of Cancer Survivorship, vol. 9, no. 3, pp. 523-531. https://doi.org/10.1007/s11764-015-0429-z1932-225910.1007/s11764-015-0429-zhttps://hdl.handle.net/20.500.14602/64044Purpose This study assessed differences in neuropathic symptoms between colorectal cancer (CRC) patients with and without diabetes. Moreover, we aimed to explore whether neuropathic symptoms could be explained by the receipt of chemotherapy as it was previously shown that cancer patients with diabetes less often receive chemotherapy. Methods Data from a cross-sectional study among CRC patients (2–11 years after diagnosis) was used. Data were collected by the Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES) registry which is linked to clinical data from the population-based Eindhoven Cancer Registry. Diabetes status was self-reported and neuropathic symptoms were measured with the European Organization for Research and Treatment of Cancer quality of life questionnaire–chemotherapy-induced peripheral neuropathy 20 (EORTC QLQ-CIPN20). Results Two hundred eighteen CRC patients with diabetes were matched on age and sex to 975 CRC patients without diabetes. After adjustments for cancer treatment including chemotherapy and other covariates, logistic regression models showed that CRC patients with diabetes experienced more mild to severe neuropathic symptoms, including tingling fingers or hands (odds ratio (OR) = 1.40; 95 % confidence interval (CI) 1.00–1.94), tingling toes or feet (OR = 1.47; 95 % CI 1.04–2.07), numbness in toes or feet (OR = 1.83; 95 % CI 1.28–2.62), and erection problems among men (OR = 1.83; 95 % CI 1.11–3.03) as compared to CRC patients without diabetes. No differences in cancer treatment were found between CRC patients with and without diabetes. Conclusion CRC patients with diabetes experienced more neuropathic symptoms, regardless of cancer treatment, suggesting that diabetes itself rather than treatment with chemotherapy results in more neuropathic symptoms among cancer patients with diabetes compared to those without. Implications for Cancer Survivors Up to 39 % of cancer survivors might expect mainly mild, neuropathic symptoms, with more symptoms among patients with co-occurring diabetes. Keywords: Colorectal cancer, Diabetes, Neuropathic symptoms, Treatment, PROFILES, Eindhoven Cancer Registryenginfo:eu-repo/semantics/closedAccessSDG 3 - Good Health and Well-beingArticleGeneral rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. - Users may download and print one copy of any publication from the public portal for the purpose of private study or research. - You may not further distribute the material or use it for any profit-making activity or commercial gain - You may freely distribute the URL identifying the publication in the public portal" Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.https://www.scopus.com/pages/publications/84939272144closed8582252319326https://research.tilburguniversity.edu/en/publications/4bbdba7e-6105-41e9-9862-afd382ab3650(c) Universiteit van TilburgVissers, P.A.J.§0000-0002-0677-888XMols, F.§0000-0003-0818-2913Thong, M.S.Y.§0000-0002-6987-705XPouwer, F.Vreugdenhil, G.van de Poll-Franse, L.V.§0000-0003-0413-6872